| Parameters | Responders, n = 10 | Partial or non-responders, n = 6 | p Value | |||
| Age, years | 55.1 (40–78) | 56.2 (47–68) | 0.87 | |||
| Gender, n (%) | 2 (20.0) | 1 (16.7) | 0.81 | |||
| Cryoglobulinaemia vasculitis duration before treatment, months | 12.5 (10–120) | 102.0 (12–192) | 0.04 | |||
| Arthralgia, n (%) | 4 (40.0) | 2 (33.3) | 0.76 | |||
| Purpura, n (%) | 8 (80.0) | 5 (83.3) | 1 | |||
| Leg ulcer, n (%) | 1 (10.0) | 1 (16.7) | 1 | |||
| Peripheral neuropathy, n (%) | 7 (70.0) | 6 (100.0) | 0.25 | |||
| Kidney involvement, n (%) | 6 (60.0) | 1 (16.7) | 0.15 | |||
| Serum creatinine, μmol/l | 70.5 (55–240) | 62.5 (46–350) | 0.41 | |||
| Glomerular filtration rate, ml/min | 64.0 (23–100) | 82.5 (16–88) | 0.96 | |||
| Haematuria, n (%) | 6 (60.0) | 1 (16.7) | 0.15 | |||
| Proteinuria, g/24 h | 0.7 (0–9) | 0.6 (0–4) | 0.19 | |||
| Gammaglobulinaemia, g/l | 10.8 (4.7–13.2) | 11.8 (5.1–22.0) | 0.51 | |||
| HCV genotype 1, n (%) | 6 (60.0) | 4 (66.7) | 1 | |||
| Liver necroinflammation score (0–3 scale)† | 2.0 (0–3) | 2.0 (0–3) | 0.89 | |||
| Liver fibrosis score (0–4 scale)† | 2.5 (0–4) | 2.5 (0–4) | 0.84 | |||
| Cirrhosis, n (%) | 3 (30.0) | 1 (16.7) | 0.49 | |||
| ALT level (baseline), IU/l | 80.3 (42–120) | 70.0 (45–100) | 0.78 | |||
| Type II cryoglobulin, n (%) | 9 (90.0) | 5 (83.3) | 1 | |||
| Cryoglobulin level (baseline), g/l | 0.9 (0.1–2.6) | 0.9 (0.1–2.9) | 0.75 | |||
| Cryoglobulin level (month +3), g/l | 0.2 (0–1.2) | 0.2 (0–2.6) | 0.93 | |||
| RF level (baseline), IU/l | 140.3 (20–945) | 65.5 (20–242) | 0.15 | |||
| RF level (month +3), IU/l | 32.4 (13–107) | 34.5 (10–58) | 0.73 | |||
| IgM level (baseline), g/l | 2.0 (1.6–2.5) | 1.4 (0.8–3.3) | 0.15 | |||
| IgM level (month +3), g/l | 1.2 (1.0–1.3) | 1.2 (0.6–2.7) | 0.90 | |||
| C4 complement level (baseline), g/l | 0.02 (0.01–0.06) | 0.09 (0.02–0.32) | 0.09 | |||
| C4 complement level (month +3), g/l | 0.12 (0.02–0.34) | 0.12 (0.09–0.31) | 0.69 | |||
| CD19+ B cell (baseline), cells/mm3 | 134.5 (97–379) | 133.5 (109–167) | 0.96 | |||
| CD19+ B cell (month +3), cells/mm3 | 2.0 (0–20) | 0.5 (0–3) | 0.45 | |||
| HCV RNA (baseline), log copies/ml | 6.0 (5.4–6.7) | 5.8 (4.3–6.1) | 0.23 | |||
| HCV RNA (month +3), log copies/ml‡ | 2.7 (2.7–3.7) | 5.9 (2.7–7.1) | 0.01 |
RF, rheumatoid factor; ALT, alanine amino transferase; HCV, hepatitis C virus.
*Except where indicated otherwise, values are the median (ranges) and at baseline.
†Liver necroinflammation and fibrosis were graded according to the Metavir scoring system. ‡HCV RNA (month +3) was evaluated 3 months after the start of antiviral treatment.